手术切除与5%5-氟尿嘧啶及光动力疗法治疗Bowen病的长期随机对照试验结果
这项多中心非劣效随机对照试验纳入250例Bowen病患者,比较5-氟尿嘧啶(5FU)、甲基氨基酮戊酸光动力疗法(MAL-PDT)与手术切除(SE)的长期疗效。4年无瘤生存累积概率SE为97.5%,5FU为86.2%,MAL-PDT为82.7%;5FU仍非劣于SE,而MAL-PDT的非劣效性未能确立。
要点
- 5FU在4年无瘤生存上仍非劣于手术切除。
- MAL-PDT未能确立相对于手术切除的非劣效性。
- 治疗后区域未观察到皮肤鳞状细胞癌发生。
核心结论
- 长期随访中,5FU和SE治疗后Bowen病额外复发风险及治疗区域发生cSCC的风险可忽略。
- 5FU仍非劣于SE,而MAL-PDT的非劣效性未能得出结论。
研究设计与样本
- 多中心、非劣效随机对照试验,250例Bowen病患者按1:1:1随机分配至5FU、MAL-PDT或SE组。
- 邀请患者于治疗后3至5年进行长期随访。
主要发现
- 随访第一年观察到27例治疗失败;长期随访中仅1例在MAL-PDT后5年出现额外复发。
- 4年无瘤生存累积概率:SE为97.5%(95%CI 90.4-99.4),5FU为86.2%(95%CI 76.4-92.1),MAL-PDT为82.7%(95%CI 72.6-89.4)。
- 无患者在治疗区域发生皮肤鳞状细胞癌(cSCC)。
关键数值与推荐
- 主要结局为治疗后4年无瘤生存累积概率,治疗失败经组织病理学确认。
- 次要终点为皮肤鳞状细胞癌(cSCC)风险。
临床怎么用
- 对于Bowen病,5FU可作为手术切除的非劣效替代选择。
- MAL-PDT长期疗效未证实非劣于手术切除,选择时需权衡。
局限性
- 23.2%的患者失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on long-term efficacy with head-to-head comparison of different treatments for Bowen's disease (BD) is lacking. OBJECTIVE: To compare the long-term efficacy of 5-fluorouracil and methylaminolevulinate photodynamic therapy (MAL-PDT) versus surgical excision (SE) in BD. METHODS: In this multicenter, non-inferiority randomized controlled trial, 250 patients with BD were invited for long-term follow-up, 3 to 5 years post-treatment. Patients had been randomly assigned to 5FU, MAL-PDT, or SE in a 1:1:1-ratio. The primary outcome was the cumulative probability of tumor-free survival 4 years post-treatment with treatment failures confirmed histopathologically. A secondary endpoint was the risk of cutaneous squamous cell carcinoma (cSCC). RESULTS: During the first year of follow-up, treatment failure was observed in 27 patients. During long-term follow-up, only 1 additional patient developed a recurrence, 5 years after MAL-PDT. The 4-year cumulative probability of tumor-free survival was 97.5% for SE (95% confidence interval (CI) 90.4-99.4), 86.2% for 5FU (95% CI 76.4-92.1), and 82.7% for MAL-PDT (95% CI 72.6-89.4). No patient developed a cSCC in the treated area. LIMITATIONS: Loss to follow-up occurred in 23.2% of patients. CONCLUSIONS: During long-term follow-up, the additional risk of recurrence of BD after 5FU and SE, and the risk of developing a cSCC from a treated BD were negligible. Treatment with 5FU remains non-inferior to SE, whereas non-inferiority of MAL-PDT could not be concluded.
引用
- Moermans MMG, Ahmady S, Nelemans PJ, et al. Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: Long-term results of a multicenter randomized controlled trial. J Am Acad Dermatol. 2025. PMID: 41391634. doi:10.1016/j.jaad.2025.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。